Brokerages Expect Cellectis SA (CLLS) to Post -$0.67 Earnings Per Share
Wall Street brokerages expect Cellectis SA (NASDAQ:CLLS) to announce ($0.67) earnings per share for the current quarter, according to Zacks. Two analysts have provided estimates for Cellectis’ earnings, with the lowest EPS estimate coming in at ($0.69) and the highest estimate coming in at ($0.64). Cellectis posted earnings of $0.02 per share during the same quarter last year, which suggests a negative year over year growth rate of 3,450%. The firm is scheduled to announce its next quarterly earnings report on Monday, March 5th.
On average, analysts expect that Cellectis will report full year earnings of ($2.77) per share for the current year, with EPS estimates ranging from ($3.11) to ($2.54). For the next financial year, analysts expect that the firm will report earnings of ($2.65) per share, with EPS estimates ranging from ($2.88) to ($2.39). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Cellectis.
CLLS has been the topic of a number of research analyst reports. Jefferies Group reiterated a “buy” rating and set a $47.00 target price on shares of Cellectis in a research report on Tuesday, September 26th. SunTrust Banks reaffirmed a “hold” rating and set a $20.00 target price on shares of Cellectis in a report on Friday, October 6th. Nomura reduced their target price on Cellectis from $49.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, September 6th. Zacks Investment Research downgraded Cellectis from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 17th. Finally, ValuEngine downgraded Cellectis from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $39.29.
Several hedge funds and other institutional investors have recently made changes to their positions in CLLS. Sphera Funds Management LTD. boosted its holdings in shares of Cellectis by 71.1% in the 3rd quarter. Sphera Funds Management LTD. now owns 348,736 shares of the biotechnology company’s stock worth $9,922,000 after acquiring an additional 144,972 shares in the last quarter. Balyasny Asset Management LLC purchased a new stake in shares of Cellectis during the 2nd quarter valued at approximately $719,000. Advisors Asset Management Inc. lifted its stake in shares of Cellectis by 1,501.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock valued at $643,000 after buying an additional 21,181 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Cellectis during the 3rd quarter valued at approximately $517,000. Finally, KBC Group NV purchased a new stake in shares of Cellectis during the 3rd quarter valued at approximately $366,000. 16.58% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/brokerages-expect-cellectis-sa-clls-to-post-0-67-earnings-per-share/1773225.html.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.